Inhaled nitric oxide for newborns with congenital diaphragmatic hernia and high lung blood pressure
Tests inhaled nitric oxide in newborns with congenital diaphragmatic hernia and pulmonary hypertension.
Plain-language title generated from the registry record
Registry title: Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia
Key facts
- Where
- Gwangju and Seoul, South KoreaSee the 4 sites
- Phase
- Phase 4
Where in South Korea
- Chonnam National University HospitalGwangju, South KoreaNo longer taking part
- Asan Medical CenterSeoul, South KoreaNo longer taking part
- Seoul National University Children's HospitalSeoul, South KoreaNo longer taking part
- Severance hospitalSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asan Medical Center
- Trial code
- NCT07247240
- Record updated
- 25 November 2025
- Original description
This multicenter, prospective, single-arm study aims to evaluate the efficacy of inhaled nitric oxide (iNO) in neonates with congenital diaphragmatic hernia (CDH) and early pulmonary hypertension. Short-term treatment response will be assessed by the changes in oxygenation index and other parameters including echocardiographic parameters at predefined intervals.Read full original descriptionShow less
Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia With Early Pulmonary Hypertension
This multicenter, prospective, single-arm study aims to evaluate the efficacy of inhaled nitric oxide (iNO) in neonates with congenital diaphragmatic hernia (CDH) and early pulmonary hypertension. Short-term treatment response will be assessed by the changes in oxygenation index and other parameters including echocardiographic parameters at predefined intervals.
Inclusion: Bochdalek type congenital diaphragmatic hernia; Gestational age at 34 weeks or more and within 14 days after birth; Hypoxic respiratory failure and pulmonary hypertension.
Exclusion: Previous treatment of pulmonary vasodilators including inhaled nitric oxide; Combined congenital heart disease requiring neonatal intervention or surgery; on ECMO treatment.